Preliminary validation of clinical remission criteria using the OMERACT filter for select categories of juvenile idiopathic arthritis.
Explore this paper's citation graph
Summary
The preliminary criteria for inactive disease, clinical remission on medication, and clinical remission off medication in children with select forms of juvenile idiopathic arthritis demonstrated moderate to excellent validity characteristics in some, but not all components of the OMERACT filter.
- Type
- article
- Published
- 2006-04-01
- Cited by
- 78
- References
- 0
- OpenAlex
- https://openalex.org/W1825102967
- Semantic Scholar
- https://api.semanticscholar.org/CorpusID:32038194
Keywords
Medicine, Construct validity, Face validity, Discriminant validity, Physical therapy
References
Cited by
- Juvenile idiopathic arthritis: an update for the clinician.
- Efectividad y seguridad del tratamiento combinado con Metotrexato y Leflunomida en la Artritis Idiopática juvenil
- Defining Juvenile Idiopathic Arthritis Remission and Optimum Time for Disease-Modifying Anti-Rheumatic Drug Withdrawal
- Juvenile Idiopathic Arthritis
- Mechanisms of disease and therapy in severe juvenile idiopathic arthritis
- Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA)
- Juvenile idiopathic arthritis of peripheral joints: quality of reporting of diagnostic accuracy of conventional MRI.
- Development and Retrospective Validation of the Juvenile Spondyloarthritis Disease Activity (JSpADA) Index
- TNF‐alpha inhibitors for juvenile idiopathic arthritis
- Comparison of treatment-response criteria for juvenile idiopathic arthritis
- Quality improvement in pediatric rheumatology: what do we need to do?
- Effect of Biologic Treatments on Growth in Children with Juvenile Idiopathic Arthritis
- Safety and immunogenicity of varicella vaccine in patients with juvenile rheumatic diseases receiving methotrexate and corticosteroids
- Remission in Juvenile Idiopathic Arthritis: Current Facts
- Efficacité et tolérance d’un traitement par anti-TNF alpha chez les patients atteints de spondylarthropathies juvéniles☆
- Current Developments in the Use of Biomarkers for Juvenile Idiopathic Arthritis
- Etanercept improves linear growth and bone mass acquisition in MTX-resistant polyarticular-course juvenile idiopathic arthritis.
- Psychometric characteristics of outcome measures in juvenile idiopathic arthritis: A systematic review
- Ghrelin levels in patients with juvenile idiopathic arthritis: relation to anti-tumor necrosis factor treatment and disease activity.
- Methods of Formal Consensus in Classification/Diagnostic Criteria and Guideline Development
Related papers
- International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001.
- Preliminary definition of improvement in juvenile arthritis.
- Preliminary criteria for clinical remission for select categories of juvenile idiopathic arthritis.
- Patterns of clinical remission in select categories of juvenile idiopathic arthritis.
- Development and validation of a composite disease activity score for juvenile idiopathic arthritis.
- Juvenile idiopathic arthritis.
- Etanercept in children with polyarticular juvenile rheumatoid arthritis. Pediatric Rheumatology Collaborative Study Group.
- Methotrexate withdrawal at 6 vs 12 months in juvenile idiopathic arthritis in remission: a randomized clinical trial.
- 2011 American College of Rheumatology Recommendations for the Treatment of Juvenile Idiopathic Arthritis: Initiation and Safety Monitoring of Therapeutic Agents for the Treatment of Arthritis and Systemic Features
- Adalimumab with or without methotrexate in juvenile rheumatoid arthritis.